Zhejiang Huahai Pharmaceutical will produce and sell Paxlovid in mainland China for five years, the companies said in separate statements. Pfizer will provide ingredients to make nirmatrelvir, the antiviral portion of the drug, and ritonavir, which slows the antiviral’s breakdown in the body. Huahai will manufacture and combine the two into Paxlovid.
Based in eastern China, Huahai is one of the nation’s biggest producers of pharmaceutical ingredients and generic drugs. In 2018, a likely carcinogen called NDMA was found in ingredients that the company manufactured and used in medicines to treat high blood pressure.
Pfizer has a rigorous quality system in place to ensure that medicines are produced in accordance with all applicable company and regulatory standards, a spokesperson said in response to questions from Bloomberg News about the Paxlovid agreement. Calls to a phone number listed on Huahai’s website went unanswered.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Sumber: BusinessTechSA - 🏆 24. / 61 Baca lebih lajut »